Policy & Regulation
Sanofi's new nirsevimab data analyses reinforce efficacy against RSV
12 May 2022 -

France based healthcare company Sanofi announced on Wednesday that results from a prespecified pooled analysis of the pivotal Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% (95% CI 65.9 to 87.7; P

Login
Username:

Password:


Related Headlines